Genetic and Signaling Pathways in Epithelial Thyroid Cancer
Genetic and Signaling Pathways in Epithelial Thyroid Cancer
批准号:
8145140
负责人:
Matthew D Ringel
金额:
$13.14万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
未结题
起止时间:
2008-03-01 至
关键词:
17-(Allylamino)-17-demethoxygeldanamycin1q414q328q24AccountingAddressAdoptedAdvanced Malignant NeoplasmAffectAgeAllelesAnimal ModelAnimalsApoptosisAreaAutopsyBRAF geneBenignBiochemicalBiological MarkersBiological ModelsBioluminescenceBiopsyBlindedBreedingCalibrationCancer ControlCancer FamilyCancer ModelCancer cell lineCandidate Disease GeneCaregiversCase-Control StudiesCell CycleCell SurvivalCell surfaceCellsChildhoodClinicClinicalClinical DataClinical PathologyClinical ResearchClinical TrialsCodeComplexComputer softwareConstitutionalConsultationsControl GroupsCopy Number PolymorphismDataDatabasesDeath CertificatesDeath RateDeletion MutationDevelopmentDiagnosisDimethyl SulfoxideDiscriminationDiseaseDisease ProgressionDoxycyclineEarly DiagnosisEndocrineEnvironmentEpithelialEventExonsExpressed Sequence TagsFamilyFamily memberFine needle aspiration biopsyFollicular thyroid carcinomaFrequenciesFunctional RNAFunctional disorderGene CombinationsGene ExpressionGene MutationGenerationsGenesGeneticGenetic PolymorphismGenetic screening methodGenome StabilityGenomic InstabilityGerm-Line MutationGlycine decarboxylaseGoalsHaplotypesHumanHuman GeneticsHyperplasiaImageIn VitroIncidenceIndividualInheritedInterest GroupInternationalInvestigationIodineKinesisKnock-outKnockout MiceKnowledgeLaboratoriesLeftLifeLiteratureLogistic RegressionsLoss of HeterozygosityLuciferasesMaintenanceMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of thyroidMediatingMesenchymalMessenger RNAMethodologyMethodsMicrosatellite RepeatsMiningModelingMolecularMolecular AbnormalityMolecular TargetMonitorMultiple Hamartoma SyndromeMusMutationMutation AnalysisNational Comprehensive Cancer NetworkNeoplasmsOncogenesOther GeneticsOutcomePTEN genePapillary thyroid carcinomaPathogenesisPathologyPathology ReportPathway interactionsPatientsPatternPenetrancePharmaceutical PreparationsPhenotypePhosphorylationPhosphorylation SitePhysiologicalPlayPolandPredispositionPreventionPrimary NeoplasmProbabilityProceduresProcessProfessional counselorProgressive DiseaseProteinsProteomicsPublic HealthPublicationsQuestionnairesRET/H4 OncogeneRNAROC CurveRadiationRadioisotopesReagentRecruitment ActivityRelative (related person)ResearchResearch PersonnelResourcesRoleSAGE LibrarySchemeSensitivity and SpecificityServicesSignal PathwaySignal TransductionSirolimusSite-Directed MutagenesisStagingStatistical ModelsSusceptibility GeneTechniquesTechnologyTestingTetracyclinesThyroid GlandThyroid NoduleThyroid carcinomaTissue MicroarrayTranscriptTransgenic MiceTransgenic ModelTranslatingTriageTumor Cell InvasionTumor Suppressor GenesUltrasonographyUnited StatesValidationVariantVimentinWestern BlottingWorkWritingXenograft Modelbasebench to bedsidecancer cellcancer geneticscarcinogenesiscell motilityclinical careclinical practiceclinically relevantcohortdata integrationdesigndiagnostic accuracydrug developmenteffective therapygene interactiongenetic linkage analysisgenome-widegenome-wide linkageimaging modalityimprovedin vivoin vivo Modelinhibitor/antagonistinterestmeetingsmembermigrationmortalitymouse modelmultidisciplinarynon-oncogenicnovelolder patientp21 activated kinasepre-clinicalpreventprobandprogramspromoterprospectiveprotein activationprotein complexproto-oncogene protein c-retresearch studyresponsesodium-iodide symportertherapeutic targetthyroid neoplasmtumortumor growthtumor initiationtumor progressiontumorigenesisuptakevalidation studies
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The incidence of thyroid cancer is rising at the second fastest rate of all malignancies in the United States and has an increasing tumor-specific mortality annually, making it an important public health problem. The reasons for this increasing incidence and rising death rate are uncertain. The goal of the P01 application is to address the key issues relating to thyroid cancer predisposition, tumorigenesis, and progression in order to enhance the potential for both early diagnosis and the effective treatment of progressive disease. Based on extensive preliminary data from our group, we propose to: (1) examine and identify predisposing genes for papillary thyroid cancer, (2) determine the critical changes responsible for the development of follicular thyroid cancer in an inherited form of the disease, Cowden syndrome, using a novel animal model, and translate this into a scheme to enhance preoperative diagnosis of this form of thyroid cancer, (3) evaluate and identify the key mechanisms of thyroid cancer induction and dedifferentiation induced by the RET/PTC 1 oncogene, one of the most common genetic abnormalities in papillary thyroid cancer, using a second novel animal model system, and (4) determine key pathways involved in tumor invasion and motility for both follicular and papillary thyroid cancers focusing on the models developed in this P01, and then test novel agents directed at blocking these pathway in vitro and in vivo. Over the past six years, the PI's of the individual projects, and the leaders of the cores have created an environment to successfully perform this integrated P01 that is unique for thyroid cancer. This includes a substantial database, integration with pathology, and a record of successful collaborative genetics, laboratory, drug development, and clinical research as evidenced by approximately thirty co-authored publications. Thus, this P01 represents an integrated Bedside-to-Bench-to-Bedside approach targeting the key clinical issues confronting the diagnosis and management of patients with thyroid cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RCAN 1.4 metastasis suppressor in thyroid cancer
-
批准号:9973560
-
项目类别:
-
资助金额:$45.25万
-
财政年份:2020
-
负责人:Matthew D Ringel
-
依托单位:
RCAN 1.4 metastasis suppressor in thyroid cancer
-
批准号:10604328
-
项目类别:
-
资助金额:$44.53万
-
财政年份:2020
-
负责人:Matthew D Ringel
-
依托单位:
RCAN 1.4 metastasis suppressor in thyroid cancer
-
批准号:10400004
-
项目类别:
-
资助金额:$44.34万
-
财政年份:2020
-
负责人:Matthew D Ringel
-
依托单位:
Role of p21-activated kinases in thyroid cancer
-
批准号:10377551
-
项目类别:
-
资助金额:$36.76万
-
财政年份:2018
-
负责人:Matthew D Ringel
-
依托单位:
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve Health
-
批准号:10414809
-
项目类别:
-
资助金额:$462.14万
-
财政年份:2018
-
负责人:Matthew D Ringel
-
依托单位:
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE
-
批准号:8741949
-
项目类别:
-
资助金额:$216.2万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
Developing Combination Therapies for Medullary Thyroid Cancer
-
批准号:8588547
-
项目类别:
-
资助金额:$28.39万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE
-
批准号:8548721
-
项目类别:
-
资助金额:$215.05万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
Integrated Clinicopathology and Biorespository Core
-
批准号:8588551
-
项目类别:
-
资助金额:$27.9万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
Administrative Core
-
批准号:8588554
-
项目类别:
-
资助金额:$25.09万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
Biostatistics Core
-
批准号:8588552
-
项目类别:
-
资助金额:$14.08万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
RCAN1 in Thyroid Cancer Progression
-
批准号:8235810
-
项目类别:
-
资助金额:$33.59万
-
财政年份:2011
-
负责人:Matthew D Ringel
-
依托单位:
RCAN1 in Thyroid Cancer Progression
-
批准号:8403904
-
项目类别:
-
资助金额:$31.35万
-
财政年份:2011
-
负责人:Matthew D Ringel
-
依托单位:
RCAN1 in Thyroid Cancer Progression
-
批准号:8784195
-
项目类别:
-
资助金额:$33.07万
-
财政年份:2011
-
负责人:Matthew D Ringel
-
依托单位:
RCAN1 in Thyroid Cancer Progression
-
批准号:8108692
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2011
-
负责人:Matthew D Ringel
-
依托单位:
Administrative Core
-
批准号:8506025
-
项目类别:
-
资助金额:$11.37万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
p21 Activated Kinase in Thyroid Cancer
-
批准号:9041531
-
项目类别:
-
资助金额:$39.31万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
Genetic and Signaling Pathways in Epithelial Thyroid Cancer
-
批准号:8064255
-
项目类别:
-
资助金额:$224.77万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
Genetic and Signaling Pathways in Epithelial Thyroid Cancer
-
批准号:9246457
-
项目类别:
-
资助金额:$229.72万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
Genetic and Signaling Pathways in Epithelial Thyroid Cancer
-
批准号:9041526
-
项目类别:
-
资助金额:$228.92万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
海外基金